失代偿期乙肝肝硬化行阿德福韦酯联合拉米夫定治疗的价值探讨

To Explore the Value of Adefovir Dipivoxil Combine With Lamivudine in Treatment of Decompensated Period of Hepatitis B Cirrhosis

目的探讨失代偿期乙肝肝硬化患者采用阿德福韦酯联合拉米夫定治疗的临床效果及安全性。方法选择2010年6月-2014年6月我院收治60例失代偿期乙肝肝硬化患者作为观察对象,将患者随机分成对照组与实验组,对照组采用拉米夫定治疗,实验组在对照组基础上加用阿德福韦酯治疗,观察两组乙肝肝硬化患者治疗后的临床疗效及不良反应的发生率。结果两组乙肝肝硬化患者治疗后的临床疗效相比,P〈0.05,差异具有统计学意义;两组乙肝肝硬化患者治疗后的不良反应发生率相比,P〉0.05,差异不具有统计学意义。结论失代偿期乙肝肝硬化患者采用阿德福韦酯联合拉米夫定治疗的临床效果显著,无明显不良反应出现,安全可靠。

Objective To study the decompensated period of hepatitis b patients with cirrhosis with adefovir ester joint lamivudine clinical effect and safety of treatment.Methods Selected 60 patients with decompensated from June 2010 to June 2014 in our hospital who had hepatitis B cirrhosis of the liver as research object, were randomly divided into the control group and the experimental group, the control group used lamivudine treatment, the experimental group on the basis of control group and treatment with adefovir ester, observe the clinical curative effect of two groups of patients with hepatitis B cirrhosis of the liver after treatment and the incidence of adverse reactions.Results Two groups of patients with hepatitis b cirrhosis of the liver compared the clinical efifcacy of difference to be markedly after treatment,P〈0.05, had difference statistically signiifcance, Two groups of patients with hepatitis b cirrhosis of the liver after treatment the incidence of adverse reactions compared,P〉0.05, had difference statistically significance.Conclusion Decompensation period of hepatitis b patients with cirrhosis with adefovir ester with lamivudine therapy clinical effect is remarkable, no obvious adverse reactions occur, safe and reliable.